demonstrated that the dual-specific antibody REGN4018, targeting highly expressed MUC16 in ovarian cancer, effectively activates T cells and kills MUC16-positive tumor cells in vitro, with preclinical animal model studies revealing that its combination with anti-PD-1 antibodies significantly enhances anti-tumor effects (88). This evidence concerns the gene MUC16 and ovarian cancer.